Gregory Lyman Condie, DO Pain Medicine - Interventional Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 84 W 4800 S, Ste 101, Murray, UT 84107 Phone: 801-261-4988 |
Kierra Law, Pain Medicine - Interventional Pain Medicine Medicare: Medicare Enrolled Practice Location: 5801 S Fashion Blvd Ste 180, Murray, UT 84107 Phone: 801-262-7246 |
Dr. Mark M Passey, MD Pain Medicine - Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 5810 S 300 E, #300, Murray, UT 84107 Phone: 801-314-2225 Fax: 801-314-2345 |
News Archive
ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida.
Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.
Findings of a new study led by Prof. XU Guowang from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences and Prof. YANG Chunzhang from the National Cancer Institute shed light on the selective therapeutics for IDH1-mutated glioma by targeting glutathione synthesis pathway.
A little vibration can be a good thing for people who need a sensitive touch. Researchers at the Georgia Institute of Technology have developed a glove with a special fingertip designed to improve the wearer's sense of touch. Applying a small vibration to the side of the fingertip improves tactile sensitivity and motor performance, according to their research results.
HemaCare Corporation announced today that the Company generated 2011 second quarter revenue of $4.2 million from continuing operations and a net loss of $252,000, or $(0.03)/share, including net income from discontinued operations of $180,000 compared to second quarter 2010 revenue from continuing operations of $3.9 million and net income of $223,000, or $.02/share, including net income of $843,000 from discontinued operations.
› Verified 1 days ago